The personalized mRNA cancer vaccine, when combined with immunotherapy, reduces the risk of melanoma recurrence and death.

Personalized mRNA cancer vaccine cut melanoma death, recurrence by 42% Markers released top-line results today after previously reporting trial succeeded. https://arstechnica.com/health/2026/10/personalized-mrna-cancer-vaccine-cut-melanoma-death-recurrence-by-42/?utm_brand=arstechnica&utm_social-type=owned&utm_source=mastodon&utm_medium=social

Moderna and Merck released Phase 3 trial data showing that their personalized ✅ mRNA cancer vaccine, #intismeran #autogene (mRNA-4157), combined with the immunotherapy Keytruda, ⭐️cut the risk of melanoma recurrence or death by 42% ⭐️and the risk of cancer spread by 38%. https://www.nytimes.com/2026/10/22/well/cancer-vaccine-melanoma-merck-moderna.html?smid=nytcore-ios-share

A Personalized Cancer Vaccine Cuts Melanoma Recurrence by 42% in New Trial Results https://time.com/article/2026/10/22/moderna-merck-immunotherapy-lowers-melanoma-recurrence/ A personalized cancer vaccine from Moderna and Merck reduced melanoma recurrence by 42% in a clinical trial, adding scientific weight to a vaccine-based approach to treating the disease. #mix #cancer-research #vaccines

A Personalized Cancer Vaccine Cuts Melanoma Recurrence by 42% in New Trial Results https://time.com/article/2026/10/22/moderna-merck-immunotherapy-lowers-melanoma-recurrence/ #mix #cancer-research #vaccines